Marwan Hariz, MD, PhD and Jordan P. Amadio, MD, MBA
Deep brain stimulation (DBS) for enhancements of non-disease states is ethically indefensible given our incomplete knowledge of this technology. Attention should instead be focused on increasing access to DBS for patients with illnesses potentially treatable by the procedure.
Concerns about the deleterious effects of stress on the mind and body have led to the beginnings of a stress vaccine, an injection that will reduce these effects.
David Elkin, MD, Erick Hung, MD, and Gilbert Villela, MD
The rapidly evolving field of neuroethics is concerned with the ethical questions that new technologies will pose about autonomy, privacy, the definition of normal, and individuality.
An interview with Allan Ramsay, one of the five appointed members of the Green Mountain Care Board, which oversees the development of Vermont’s single-payer health care system.
This month theme issue editor, Trahern Jones, a fourth-year student at Mayo Medical School in Rochester, Minnesota, spoke with Dr. Edward Laskowski about the use of performance-enhancing drugs and substances among athletes today.
Is it ethical to create and advertise, either publicly or during office visits, package deals that offer patients an incentive to have procedures they are not already seeking and might not have considered?
Within the patient-physician relationship, the request for neuroenhancement becomes a chief concern, and the physician has a duty to take a history and perform a physical exam to determine whether the patient’s current level of function represents significant change.
Physicians have an ethical responsibility to caregivers whose psychological distress is caused by their experience of the patient’s illness and treatment.
AMA J Ethics. 2017;19(5):493-500. doi:
10.1001/journalofethics.2017.19.5.msoc3-1705.